FORM PTO-1390 (REV. 11-2000) U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY 'S DOCKET NUMBER: USV-3.2.003/3909

U S APPLICATION NO (If known, see 37 CFR 1 5): 09/857077

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/IB00/01404	02 October 2000 (02-10-00)	02 October 2000 (02-10-00)

TITLE OF INVENTION: SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING METFORMIN AND METHOD OF ITS PRODUCTION

APPLICANT(S) FOR DO/EO/US: Gidwani, Suresh Kumar; Singnurkur, Purushottam; Tewari, Prashant Kumar

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. [X] This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. [ ] This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. [X] This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. [ ] The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
   a. [ ] is attached hereto (required only if not communicated by the International Bureau).
   b. [X] has been communicated by the International Bureau.
   c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
6. [X] An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. [ ] is attached hereto.
   b. [ ] has been previously submitted under 35 U.S.C. 154(d)(4).
7. [ ] Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3))
   a. [ ] are attached hereto (required only if not communicated by the International Bureau).
   b. [ ] have been communicated by the International Bureau.
   c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
   d. [ ] have not been made and will not be made.
8. [ ] An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. [ ] An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [X] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [ ] A FIRST preliminary amendment.
14. [ ] A SECOND or SUBSEQUENT preliminary amendment.
15. [ ] A substitute specification.
16. [ ] A change of power of attorney and/or address letter.
17. [ ] A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. [ ] A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. [ ] A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. [X] Other items or information: - Certificate of Express Mail 37 CFR 1.10

21. x Other - Acknowledgment Postcard

INTERNATIONAL APPLN	INTERNATIONAL FILING DATE	DOCKET
PCT/IB00/01404	02 OCTOBER 2000	USV-3.2.003/3909

09/857077
JC18 Rec'd PCT/PTO 31 MAY 2001

☒ The following fees are enclosed:

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	$1000.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	$860.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	$710.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	$690.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	$100.00	$ 860	
Surcharge of $130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		$	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	$
Total claims	14 - 20 =	0	x $18.00	$ 0
Independent claims	2 - 3 =	0	x $80.00	$ 0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ $270.00	$ 0
TOTAL OF ABOVE CALCULATIONS =				$ 860
☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			+	$
SUBTOTAL =				$ 860
Processing fee of $130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				$
TOTAL NATIONAL FEE =				$ 860
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). $40.00 per property +				$ 40
TOTAL FEES ENCLOSED =				$ 900
			Amount to be refunded:	$
			charged:	$

a. ☒ A check in the amount of $ 900 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of $ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-2317 . A duplicate copy of this sheet is enclosed.

☐

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO
Cobrin & Gittes
750 Lexington Avenue
New York, N.Y. 10022
Phone: (212) 486-4000

Robert Hess
SIGNATURE

Robert J. Hess
NAME

32,139
REGISTRATION NUMBER

SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING METFORMIN AND METHOD OF ITS PRODUCTION

Field of the Invention

The present invention relates to sustained release pharmaceutical preparations containing metformin hydrochloride which provides sustained release of metformin hydrochloride over a prolong period of time and a method of producing it.

Metformin hydrochloride is a well known biguanide derivative (1,1-dimethylbiguanide monohydrochloride) which is widely used as oral antihtperglycemic agent in the management of noninsulin dependent diabetes mellitus (NIDDM).

Metformin hydrochloride being a highly water soluble drug (>300 mg/ml at 25°C), leads to the difficulty in making a sustained release dosage form.

Marketed preparations available earlier with 850 mg dose of metformin hydrochloride having label of retard tablets (Glucophase RTM retard) have not been able to demonstrate any advantage in a limited volunteer trials. This probably attributable to poor choice of polymers and low dosage, desired for sustained action.

US patent 5,955,106 by Moeckel, J. describes the process of making metformin hydrochloride 850 mg retard tablet containing hydrocolloid forming retarding agents and further control of release provided by film envelop. It

however does not provide any justification for using 850 mg dose of metformin hydrochloride for delayed release preparation and the expected release rates from such compositions. This patent also does not give any in-vitro and in-vivo data to support its claims. Literature survey indicates metformin hydrochloride has only 40% to 60% bioavailability with high renal clearance. Hence the dose 850 mg may be insufficient to achieve therapeutic plasma concentration, around 1 µg/ml for a sufficient period of time and might require to take such tablets twice or thrice a day.

WP patent 99/47128 by Timmins et al describes a biphasic controlled release delivery system for metformin hydrochloride with inner solid particulate phase and outer solid continuos phase utilizing hydrophilic and hydrophobic polymers. These tablets are hydrodynamicaly balanced and swells upto approximately three times its dry size following hydration However it is well documented that in supine position the tablet escapes through the pylorus of the stomach after administration, which may deteriorate the tablet's in-vivo performance. Also volume desired to maintain floating of the tablet is never enough in the stomach except in fed condition. Hence making such system is doubtful with reference to its performance. Another major limitation of this patent is about dosage of the metformin hydrochloride and formulation. For instance, examples cited provides formulation of 500 mg metformin hydrovchloride with tablet weight of approximately 1.0 gm . Hence restricting to the use of low dose sustained release tablets of 500 mg or slightly more only and making it obligatory to take two tablets of 500 mg each time to provide sustained action.

The present invention is based on the scientific calculation of dose of metformin hydrochloride desired, based on the data available from in-vivo studies which are well documented in the scientific literature. The model used here is based on the mathematical equations provided by Dobrinska and Welling (1975) which gives fairly accurate calculations about loading dose and maintenance dose for achieving sustained release effect.

The dose of metformin hydrochloride is calculated by considering the following pharmacokinetic values from the literature.

Plasma concentration Cmax = 1.02 µg/ml

Elimination half life t 1/2 = 6.2 hours.

Volume of disribution Vd = 275 litrs.

Renal clearance = 552± 139 Litrs/min.

Total clearance = 1300 ml/min.

Using Dobrinska and Welling model, the calculated loading dose is 283 mg and maintenance dose is 759 mg and the total dose is 1040 mg of metformin hydrochloride for achieving sustained release effect for 24 hours.

The object of the present invention is to prepare palatable and swallowable pharmaceutical preparation containing as high as approximately 1.0 gm metformin by suitable technology showing demonstrable release rate and facilitated in-vivo absorption for the desired period. The emphasis is to develop simple monolithic system composed of hydrophobic polymers and other excepients with improved kinetics of extended release dosage forms and with highest possible content of active substance and the simplest method of producing it.

The monolithic sustained release system of the invention is a homogeneous system composed of active drug in an amount within the range of 60 to 90% by weight, preferably 70 to 80% by weight, and one or more hydrophobic polymers or one or more other type of hydrophobic materials. In an amount within the range of about 15 to 40% by weight, preferably 20 to 30 % by weight based on the weight of the active substance.

Hydrophobic polymers which may be employed for the monolithic sustained release system in the present invention include, but not limited to stearic acid, glycerylmonostearate, glyceryl behenate, glyceryl monooleate, glyceryl palmitostearate, microcrystalline wax, stearyl alcohol, cetyl alcohol, cetostearyl alcohol, hydrogenated castor oil, tristearin, waxes, polyethylene powder, polyvinyl chloride, shellac, rosin, and the like. Where the mixtures of the hydrophobic polymer will be employed in weight ratio to other hydrophobic material within the range of about 1: 0.01 to 1: 5 , preferably about 1 : 0.3

The pharmaceutical compositions according to the present invention can be used to produce compressed tablets of any shape, preferably oval shape and can be additionally provided with film coat of commonly used hydrophilic coating polymers. The film envelop used cane a taste neutralizing film forming agent to which dies can optionally be added can be used for elegance. The proportion by weight of the film envelop relative to the final tablet is in the usual range of 0.5 to 4.0% by weight preferably 1.0 to 1.5% by weight. Film formers such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, starch, cellulose derivatives and the like.

The monolithic composition according to the present invention can also be used to produce compressed slugs and filled into capsules.

Auxiliary substances which may be employed for monolithic sustained release system in the present invention include, binder, like polyvinyl pyrrolidone, gelatin, gum acacia, Klucel EF (hydroxypropyl cellulose), carboxymethyl cellulose sodium, etc.; Where as the glidants include, but not limited to colloidal siliconedioxide, talc, starch, and the like; lubricants include, but not limited to magnesium stearate, zinc stearate, and the like

The pharmaceutical dosage form according to the present invention such as tablet, apart from active drug and hydrophobic polymers and or hydrophobic materials may contain 1.0 to 15 % by weight of a binder, preferably 3.0 to 10 % by weight ; and upto 2.0 % by weight of glidant preferably 0.5 to 1.0 5 by weight; and upto 2.0 % by weight of lubricants preferably 0.5 to 1.0 % by weight ; each in relation to the tablet weight.

In the present invention the pharmaceutical composition, such as tablets are produced by dry mixing of active substance and optionally further auxiliary substance and granulating this mixture with hydrophobic polymers and or other hydrophobic materials by hot melt granulation technique using jacketed rapid mixer granulator at a temperature 40 to 120 °C, preferably 60 to 80 °C. This is followed by gradually cooling the granulate mass to the room temperature with continuos mixing. The resulting mass is further granulated with aqueous or organic solution of the binder followed by drying and converting it into 30 µm to 2.0 mm granules, preferably 100 µm to 1.0 mm by

milling and sizing. Subsequently appropriate other pharmaceutical auxiliary substances are admixed with the sized granules.

In the present invention the pharmaceutical composition, such as tablets are also produced by dry mixing of active substance, optionally further auxiliary substances, hydrophobic polymers and or another hydrophobic materials and binder in extruder. This mixture is extruded at a temperature 40 to 120 °C , preferably 60 to 90 °C in a simple extruder used for injection molding of plastics, followed by extrusion of the melted homogeneous mass with gradual cooling to room temperature and converting into 30 to 2.0 µm to 2.0 mm granules, preferably 100 µm to 1.0 mm by milling and sizing. Subsequently appropriate other pharmaceutical auxiliary substances are admixed with the sized granules.

The composition produced in this manner is subsequently processed in the usual manner to produce pharmaceutical dosage forms, such as e.g. Compressed into tablets or filling of pressed slugs into capsule. The tablets can be coated with a film using the standard coating processes and methods such as conventional coating pan or fluid coating process.

The sustained release tablets according the present invention release metformin hydrochloride in a controlled manner which is suppose to provide an effect over a time period upto 24 hours, preferably over 18 hours as per the calculations.

Useful metformin sustained release formulations as per the invention shows the following in-vitro drug release characteristics when tested in gastric fluid pH 1.2 for first hour and then in phosphate buffer pH 6.8 USP.

Time	% Release
1	38 – 45%
2	50 – 55 %
3	62 – 68 %
4	70 – 75 %
5	80 – 85 %
6	85 – 90 %
7	91 – 95 %
8	96 – 100 %

Example 1 :

225 gm of stearic acid was melted at 70°C temperature. 1000 gm metformin hydrochloride was heated to 70°C in a jacketed rapid mixer granulator and granulated with above melted stearic acid at 70°C temperature. After granulation the granulate mass was mixed continuously with gradual cooling to room temperature.

60 gm of shellac and 25 gm of polyvinyl pyrollidone were dissolved in 150 gm of isopropyl alcohol. This solution was gradually added to above metformin stearic acid granulate and mixed till dough mass formed. The resulting dough mass was dried at 45°C for 2 hours and then sized through 2.4 mm screen to break the agglomerates. These sized granules (1310 gm) were blended with 4.0 gm of colloidal silicone dioxide and 8.0 gm of magnesium stearate and compressed into capsule shape oval tablets of each containing 1000 mg of metformin hydrochloride.

The in-vitro release of metformin hydrochloride form these tablet was as follows.

Time (Hrs)	% Release
1	40 %
2	55 %
3	65 %
4	75 %
5	82 %
6	89 %
7	95 %
8	99.5 %

Example 2 :

225 gm of stearic acid , 1000 gm metformin hydrochloride, 60 gm of shellac and 25 gm of polyvinyl pyrollidone were mixed in the extruder at 70°C and extruded and then gradually cooled to room temperature. The resulting agglomerates were sized through 2.4 mm screen . These sized granules (1310 gm) were blended with 4.0 gm of colloidal silicone dioxide and 8.0 gm of magnesium stearate and compressed into capsule shape oval tablets of each containing 1000 mg of metformin hydrochloride.

The in-vitro release of metformin hydrochloride form these tablet was as follows

Time (Hrs)	% Release
1	42 %
2	57 %
3	68 %

4	77 %
5	84 %
6	90 %
7	96 %
8	100 %

Example 3 :

250 gm of glyceryl mono stearate was melted at 70°C temperature. 1000 gm metformin hydrochloride was heated to 70°C in a jacketed rapid mixer granulator and granulated with above melted stearic acid at 80°C temperature. After granulation the granulate mass was mixed continuously with gradual cooling to room temperature.

60 gm of shellac and 25 gm of polyvinyl pyrollidone were dissolved in 150 gm of isopropyl alcohol. This solution was gradually added to above metformin stearic acid granulate and mixed till dough mass formed. The resulting dough mass was dried at 45°C for 2 hours and then sized through 2.4 mm screen to break the agglomerates. These sized granules (1335 gm) were blended with 4.0 gm of colloidal silicone dioxide and 8.0 gm of magnesium stearate and compressed into capsule shape oval tablets of each containing 1000 mg of metformin hydrochloride.

The in-vitro release of metformin hydrochloride form these tablet was as follows.

Time (Hrs)	% Release
1	39 %
2	52 %
3	61 %
4	72 %
5	80 %
6	88 %
7	94 %
8	98 %

Example 4 :

175 gm of polyethylene powder , 1000 gm metformin hydrochloride and 25 gm of polyvinyl pyrollidone were mixed in the extruder at 70°C and extruded and then gradually cooled to room temperature. The resulting agglomerates were sized through 2.4 mm screen . These sized granules (1200 gm) were blended with 4.0 gm of colloidal silicone dioxide and 8.0 gm of magnesium stearate and compressed into capsule shape oval tablets of each containing 1000 mg of metformin hydrochloride.

The in-vitro release of metformin hydrochloride form these tablet was as follows.

Time (Hrs)	% Release
1	48 %
2	54.2 %

3	64 %
4	73.4 %
5	82 %
6	90.3 %
7	96 %
8	99.7 %

Example 5 :

160 gm of polyvinyl chloride powder , 1000 gm metformin hydrochloride and 25 gm of polyvinyl pyrollidone were mixed in the extruder at 70°C and extruded and then gradually cooled to room temperature. The resulting agglomerates were sized through 2.4 mm screen . These sized granules (1185 gm) were blended with 4.0 gm of colloidal silicone dioxide and 8.0 gm of magnesium stearate and compressed into capsule shape oval tablets of each containing 1000 mg of metformin hydrochloride.

The in-vitro release of metformin hydrochloride form these tablet was as follows.

Time (Hrs)	% Release
1	42 %
2	53.1 %
3	62,5 %
4	72 %
5	80 %
6	85 %
7	94 %
8	98.8 %

Example 6 :

230 gm of hydrogenated castor oil was melted at 70°C temperature. 1000 gm metformin hydrochloride was heated to 70°C in a jacketed rapid mixer granulator and granulated with above melted stearic acid at 70°C temperature. After granulation the granulate mass was mixed continuously with gradual cooling to room temperature.

60 gm of shellac and 25 gm of polyvinyl pyrollidone was dissolved in 150 gm of isopropyl alcohol. This solution was gradually added to above metformin stearic acid granulate and mixed till dough mass formed. The resulting dough mass was dried at 45°C for 2 hours and then sized through 2.4 mm screen to break the agglomerates. These sized granules (1315 gm) were blended with 4.0 gm of colloidal silicone dioxide and 8.0 gm of magnesium stearate and compressed into capsule shape oval tablets of each containing 1000 mg of metformin hydrochloride.

The in-vitro release of metformin hydrochloride form these tablet was as follows.

Time (Hrs)	% Release
1	41 %
2	53 %
3	66 %
4	74.9 %
5	83 %
6	91 %
7	96.2%
8	100 %

References :

1. Moeckel, J., Gabel, R., Woog, H., [1997] , U.S. Patent 5,955,106.
2. Timmins, P., Vyas, K., [1999] , World Patent WO 99/47128.
3. Noel, M., (1980) , Jounal of International Biomedical Information and Data (IBID), 1 (1) , 9 – 20.
4. Kenneth, C., Ralph, A. D., (1998) , Diabetes Reviews, 6 (2) , 89 – 131.
5. Nancy C. Sambol, Jaine Chaing, Michael O'Conner, Chui Y. Liu, (1196), J. Clin. Pharmacol., 36 , 1012 –1021.
6. Physician Desk reference, Edition 58, (2000), Medical economic company Inc. NJ 07645-1742, Glucophase® , page 831–835.

CLAIMS :

1. Monolithic pharmaceutical composition comprising metformin hydrochloride as the active substance and hydrophobic polymer and or other hydrophobic material.
2. Composition of claim 1, wherein the sustained release dose for metformin hydrochloride is at least 1000 mg.
3. Composition of claim 1, wherein at least 74 % by weight of the composition is metformin hydrochloride.
4. The pharmaceutical formulation as defined in claim 1, wherein the hydrophobic polymer and or hydrophobic material is selected from the group consisting of Fatty acids, Fatty alcohols, Fatty acid esters, Hydrogenated oils, waxes and natural resins.
5. Composition of claim 4, wherein the hydrophobic polymer and or hydrophobic material comprises stearic acid, glyceryl monostearate, glyceryl behenate, glyceryl pamitostearate, glyceryl monooleate, microcrystalline wax, stearyl alcohol, cetyl alcohol, cetostearyl alcohol, hydrogenated castor oil, tristearin, shellac, rosin, polyvinyl chloride powder, polyethylene powder, and the like.
6. Composition of claim 1, further comprising about 3 to 10% by weight binder, up to 0.5 to 1.5% by weight glidant and up to 0.5 to 1.0% by weight of the lubricant.
7. Composition of claim 1, wherein pharmaceutical composition is tablet.

8. Process of producing a sustained release metformin hydrochloride composition of claim 1 which can be compresses comprising :

i) Granulating metformin hydrochloride and hydrophobic polymer and or other hydrophobic material by hot melt granulation or by extrusion.

ii) And drying the granulated product.

9. Process of claim 8, wherein the aqueous or organic solvent used in the granulation step contains a binder.

10. Process of claim 8, including the further step of compressing the dried granulated product into tablets.

11. Process of claim 10, including the further step of coating the tablet with a film envelope for taste neutralization.

12. Process of claim 10, wherein the compacted product further includes up to 1.5% by weight of lubricant, upto 1% by weight of glidant, and up to 4.5%by weight of binder.

13. The pharmaceutical composition according to claim 1 which releases metformin hydrochloride in a controlled and reproducible manner right from start and in the duration of minimum 8 hours.

14. The pharmaceutical composition of claim 1, used as oral antihtperglycemic agent in the management of noninsulin dependent diabetes mellitus (NIDDM).

* * * * *

ABSTRACT

Monolithic pharmaceutical composition containing metformin hydrophobic polymer and/or other hydrophobic material. Process of producing a sustained release of the composition that includes granulating metformin hydrochloride and hydrophobic polymer and/or other hydrophobic material by hot melt granulation or by extrusion and drying the granulated product.

Attorney Docket: USV-3.2.003/3909

DECLARATION FOR PATENT APPLICATION

As a below named inventors, we hereby declare that:

Our residences, post office addresses and citizenship are as stated below next to our names.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING METFORMIN AND METHOD OF ITS PRODUCTION, the specification of which is attached hereto unless the following is checked:

__X__ was filed on 02 October 2000 as United States Application Number or PCT International Application Number PCT/IB00/01404
and was amended on _____ (if applicable).

We hereby state that we have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.
We hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s):			Priority Claimed
(Number)	(Country)	(Day/Month/Year Filed)	__ Yes __ No
(Number)	(Country)	(Day/Month/Year Filed)	__ Yes __ No

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

We hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

PCT/IB00/01404 (Application Number)	02 October 2000 (Filing Date)	Pending (Status - patented, pending, abandoned)
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Peter T. Cobrin, Reg. No. 24,117, Marvin S. Gittes, Reg. No. 24,350, Richard M. Lehrer, Reg. No. 38,536, Robert J. Hess, Reg. No. 32,139, David W. Denenberg, Reg. No. 40,968, Michael A. Adler, Reg. No. 38,810 and Lawrence E. Russ, Reg No. 35,342

Address all correspondence to: COBRIN & GITTES
750 Lexington Avenue - 21st Floor
New York, New York 10022
Tel (212) 486-4000 - Fax (212) 486-4007

We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

100

Full name of sole or first inventor (given name, family name) Suresh Kumar GIDWANI
Inventor's signature Suresh Kumar **Date:** 17th May, 2001
Residence: Mumbai, INDIA IND **Citizenship:** INDIA
Post Office Address: B.S.D. marg. Station Road, Govandi
MUMBAI 400088, INDIA

200

Full name of second joint inventor (given name, family name) Purushottam SINGNURKAR
Inventor's signature Purushottam **Date:** 17th May, 2001
Residence: Mumbai, INDIA IND **Citizenship:** INDIA
Post Office Address: B.S.D. marg. Station Road, Govandi
MUMBAI 400088, INDIA

__X__ Additional inventors are being named on separately numbered sheets attached hereto.

Burden Hour Statement: This form is estimated to take .4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Office of Assistance Quality and Enhancement Division, Patent and Trademark Office, Washington, D.C. 20231, and to the Office of information and Regulatory Affairs, Office of Management and Budget (Project 0651-0032), Washington, D.C. 20503. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

DECLARATION FOR PATENT APPLICATION Page 2

Title: SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING METFORMIN AND METHOD OF ITS PRODUCTION

300

Full name of third joint inventor (given name, family name) Prashant Kumar TEWARI
Inventor's signature _____ **Date:** 17th May, 2001
Residence: Mumbai, INDIA IN X **Citizenship:** INDIA
Post Office Address: B.S.D. marg. Station Road, Govandi
MUMBAI 400088, INDIA

Full name of fourth joint inventor (given name, family name) _____
Inventor's signature _____ **Date:** _____
Residence: _____ **Citizenship:** _____
Post Office Address: _____

___ Additional inventors are being named on separately numbered sheets attached hereto.